N4 Pharma Plc the specialist preclinical stage biotech company announces a new lead programme, N4 101. This orally-delivered inflammation inhibitor for Irritable Bowel Disease (IBD) uses Nuvec®, the company’s novel silica non-viral, non-lipid nanoparticle delivery system, to overcome the challenges with current IBD treatments.